SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (15669)2/10/2005 5:21:58 PM
From: nigel bates  Respond to of 52153
 
Interesting idea. (CRXA)

$1.25 billion accumulated deficit (!)
$100m convertible due 2008.
$30m forecast burn for 2005.

Royalties on Zevalin, Bexxar, potentially various GSK vaccines...
a shedload of antigen IP with associated license deals for diagnostics & antibodies...
Early stage TLR4 program.

Results due soon - depending on cash, maybe worth a flutter.
(If GSK are really confident about their Cervarix sales, then they ought to buy them.)